Martin Borch Jensen serves as Chief Scientific Officer at GordianBio, specializing in in vivo pooled therapeutic screens within gene therapy and aging biology. He contributes to Impetus Grants and Norn Group, promoting longevity research and scientific talent mobility. Formerly a K99 Fellow at the Buck Institute, Jensen actively advances aging biology and drug development through research leadership and community engagement.

‌